People who have received the Johnson & Johnson (J&J) covid-19 vaccine can benefit from a booster dose from Pfizer or Moderna, showed preliminary results of an American study published on Wednesday (13).
The study, funded by the National Institutes of Health (NIH), was eagerly awaited in the United States because it looked at the possibility of “mixing” vaccines, using an immunizer different from the initial doses for the booster vaccine, which is currently not allowed. in the country.
The study was conducted on 458 adults vaccinated with one of three US-approved brands (Pfizer, Moderna or J&J) for at least 12 weeks.
Each of these three groups was divided into three new groups to receive one of the available vaccines as a booster. The nine groups consisted of about 50 people each.
The researchers then tested antibody levels 15 days after the booster vaccine.
For people initially inoculated with J&J, antibody levels were four times higher after a J&J boost, 35 times higher after a Pfizer boost, and 76 times higher after a Moderna boost.
And antibody levels for those who originally received the Moderna injections were higher “regardless of the booster vaccine given,” compared to those who initially received Pfizer or J&J, according to the study.
The study emphasizes that no health problems were identified after administration of booster doses.
However, the study, which has not yet been peer-reviewed, has several limitations. The number of participants was small and the immune response can evolve over time, beyond the 15 days observed during the study.
“It’s important not to get carried away by discoveries,” tweeted Peter Hotez, a professor at Baylor College of Medicine.
The results of testing a second J&J booster vaccine conducted by the company itself were “impressive,” he said.
The NIH study is expected to prompt discussions by a committee of experts at the US Food and Drug Administration (FDA), which is scheduled to review requests for booster shots from Moderna and J&J this Thursday and Friday, respectively. .
A Pfizer booster has already been approved in the United States for certain populations, such as people 65 and older, adults with high-risk medical conditions, and those in jobs where they are frequently exposed to coronavirus.
+ Until 2019, there were more people in prisons than on the Brazilian stock exchange
+ Aloe gel in the drink: see the benefits
+ Lemon-squeezing trick becomes a craze on social media
+ Chef playmate creates aphrodisiac recipe for Orgasm Day
+ Mercedes-Benz Sprinter wins motorhome version
+ Anorexia, an eating disorder that can lead to death
+ US agency warns: never wash raw chicken meat
+ Yasmin Brunet breaks the silence
+ Shark is captured in MA with the remains of youngsters missing in the stomach
+ See how much it costs to eat at the MasterChef judges’ restaurants
+ Auction of cars and motorcycles from Kombi to Nissan Frontier 0km